Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Non-regulated
PRESS RELEASE   Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration...
Read More
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces further strengthening of the intellectual property portfolio for its DSR (Direct Sodium Removal) program. A key composition of matter patent...
Read More
PRESS RELEASE   Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file IND[i] application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of DSR 2.0,...
Read More
PRESS RELEASE   Data from GLP[i] animal studies demonstrate safety of second-generation DSR[ii] product (DSR 2.0) Data from Phase 1 study of DSR 2.0 in Mexico (CHIHUAHUA) and IND[iii] filing to US FDA expected in Q1 2023 Planning to start MOJAVE, a US Phase 1/2a randomized controlled multi-center study of DSR 2.0, in Q2 2023...
Read More
PRESS RELEASE   Ghent, Belgium – 2 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its full year results ended 31 December 2022 on Thursday, 9 February 2023. The management team will...
Read More
PRESS RELEASE Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. US patent number 11,559,618...
Read More
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place from 15 to...
Read More
  Presentation by Dr. Florence Wong on Sunday November 6th in Washington, DC: “An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites” Ghent, Belgium – 21 October 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the...
Read More
Ghent, Belgium – 1 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, will announce its half year results ended 30 June 2022 on Thursday, 8 September 2022. The management team will host a...
Read More
Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive...
Read More
1 2 3 4 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES